Boston‑area startup Nido Biosciences announced it will wind down after Phase II data fell below expectations, while Genmab terminated development of acasunlimab, a bispecific antibody that BioNTech had previously exited. The twin exits highlight continuing pipeline volatility as companies triage portfolios after disappointing clinical readouts. Nido’s closure underscores the financial and operational fragility of small biotechs facing negative mid‑stage data. Genmab’s decision to stop acasunlimab follows partner withdrawals and indicates how partnership dynamics and program performance jointly drive go/no‑go decisions. Investors and R&D teams will reassess resource allocation across similar modality and target classes.